^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    γ-secretase inhibitor

    Related drugs:
    10d
    To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=20, Completed, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany | Active, not recruiting --> Completed
    Trial completion
    |
    Ogsiveo (nirogacestat) • midazolam hydrochloride • omeprazole
    21d
    Nirogacestat in Patients With Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, AIDS Malignancy Consortium
    New P2 trial
    |
    CD4 (CD4 Molecule)
    |
    Ogsiveo (nirogacestat)
    27d
    A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2032 --> Apr 2027
    Trial completion date
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Ogsiveo (nirogacestat)
    1m
    Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) (clinicaltrials.gov)
    P4, N=50, Recruiting, SpringWorks Therapeutics, Inc.
    Trial initiation date
    |
    Ogsiveo (nirogacestat)
    1m
    A Study of Nirogacestat in Japanese Adults With Desmoid Tumors/Aggressive Fibromatosis (DT/AF) (clinicaltrials.gov)
    P2, N=20, Active, not recruiting, SpringWorks Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Dec 2030 --> Oct 2029 | Trial primary completion date: May 2028 --> Mar 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Ogsiveo (nirogacestat)
    1m
    Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat (clinicaltrials.gov)
    P1, N=24, Completed, SpringWorks Therapeutics, Inc. | Recruiting --> Completed
    Trial completion
    |
    Ogsiveo (nirogacestat)
    1m
    To Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Adult Male Participants (clinicaltrials.gov)
    P1, N=20, Active, not recruiting, SpringWorks Therapeutics, Inc. | Recruiting --> Active, not recruiting | Trial completion date: Oct 2026 --> Mar 2026
    Enrollment closed • Trial completion date • Trial initiation date
    |
    Ogsiveo (nirogacestat) • midazolam hydrochloride • omeprazole
    2ms
    A Varegacestat Hepatic Impairment Study (clinicaltrials.gov)
    P1, N=35, Completed, Immunome, Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    varegacestat (AL102)
    3ms
    NIR-DT-106: Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants (2025-521402-18-00)
    P1, N=16, Active, not recruiting, Springworks Therapeutics Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Ogsiveo (nirogacestat)
    3ms
    NIR-DT-401: An Open-label, Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumor/Aggressive Fibromatosis (DT/AF). (2024-515215-21-00)
    P4, N=47, Recruiting, Springworks Therapeutics Inc.
    New P4 trial
    |
    Ogsiveo (nirogacestat)
    3ms
    NIR-DT-106: Phase 1 Study to Determine the Effect of CYP Induction Following Administration of Nirogacestat in Healthy Men Participants (2025-521402-18-00)
    P1, N=16, Recruiting, Springworks Therapeutics Inc.
    New P1 trial
    |
    Ogsiveo (nirogacestat)
    3ms
    A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery (clinicaltrials.gov)
    P2, N=35, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2032
    Trial completion date
    |
    CTNNB1 (Catenin (cadherin-associated protein), beta 1)
    |
    Ogsiveo (nirogacestat)